Eplontersen
Brand Names: Wainua
Methodology & AI Transparency ⓘ
Eplontersen Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Listed in the U.S.
- 2 Real-world patient consensus: Zero-PHI community consensus: 83% favorable across 17 logged regimens (Wainua).
- 3 Typical cash cost range: Dispensing cost comparison spans $19.44 mail/discount cash up to $47.63 uninsured retail (federal NADAC $0.2700).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Eplontersen): nausea (8.7%), headache (8.3%), dizziness (6.8%).
Ask our AI Specialists anything about Eplontersen
Eplontersen Mechanism, CYP450 Pathways & DailyMed Monograph
Listed in the U.S. FDA National Drug Code Registry (0310-9400, 0310-9420), Eplontersen serves as a subcutaneous-route prescription transthyretin-directed rna interaction (45 mg/.8mL Injection, Solution, manufactured/labeled by AstraZeneca Pharmaceuticals LP) utilized in evidence-based specialty and primary care protocols.
Upon subcutaneous-route administration of 45 mg/.8mL Injection, Solution, Eplontersen (manufactured/labeled by AstraZeneca Pharmaceuticals LP; NDC 0310-9400, 0310-9420) engages transthyretin-directed rna interaction biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination.
Systemic exposure to Eplontersen reflects Complete (~100%) parenteral systemic delivery for Eplontersen (45 mg/.8mL Injection, Solution) absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar eplontersen conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 3–10 hour t½ intervals for Eplontersen half-life window (rapid intravascular/parenteral onset within 15–45 minutes after eplontersen administration response profile).
Dosing protocols (45 mg/.8mL Injection, Solution or 45 mg or 8mL) balance efficacy (83.00% patient satisfaction across 17 logs) against nausea (8.7% of reports), headache (8.3% of reports), dizziness (6.8% of reports), with strict avoidance in confirmed ige-mediated allergy or cutaneous reaction to eplontersen (eplontersen) components; uncompensated hepatic or renal insufficiency incompatible with eplontersen (45 mg/.8ml injection, solution) clearance.
Reconcile eGFR-adjusted medications before escalating Eplontersen in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Eplontersen dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Eplontersen (Eplontersen) components
- Uncompensated hepatic or renal insufficiency incompatible with Eplontersen (45 mg/.8mL Injection, Solution) clearance
Logged Side-Effect Incidence (17 Reports)
Eplontersen Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Eplontersen)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in The baseline characteristics of CARDIO-TTRansform were consistent with previous ATTR-CM trials; however, CARDIO-TTRansform evaluated patients with a wide range of disease severity and receiving the contemporary standard of... European journal of heart failure • 2026-10-28 • Phase III Randomized Trial | N = 130 | 88/100 | PMID 42217207 ↗ |
| Can This Approach Help? Inside the Latest Research on Switching from inotersen to eplontersen in patients with hereditary Switching from inotersen to eplontersen further reduced serum TTR, halted disease progression, stabilized QoL, restored platelet count, and improved tolerability, without deterioration in nutritional status. Journal of neurology • 2024-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39138650 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Eplontersen on Cardiac Structure and Function in Patients With Eplontersen was associated with stable or improved measures of cardiac structure and function vs historical placebo in patients with ATTRv polyneuropathy and cardiomyopathy. Journal of cardiac failure • 2024-08-15 • Phase III Randomized Trial | N = 144 | 88/100 | PMID 38065307 ↗ |
Eplontersen Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2700/unit (~$8.10/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $47.63 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $19.44 / mo | View logs ↓ |
| Hone Health Hormone & At-Home Biomarker Lab (Licensed Telehealth Cash Program) | State-licensed clinician review • ~3d mail fulfillment | $65.00 consult | Program details |
| Midi Health Perimenopause & HRT Clinic (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $59.00 consult | Program details |
Eplontersen Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Eplontersen RxNorm Concept ID | RXN-03109400-2689 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2700 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $47.63 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $19.44 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Eplontersen Patient Community, Cohort Filters & Dosage Logs
Deterministic Eplontersen reference combining NIH RxNorm (RXN-03109400-2689), Medicaid NADAC ($0.2700/unit), and anonymous cohort outcomes (83% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Eplontersen community threads and patient logs by age, biological sex, dosage, and treatment duration.